Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health Inc. filed an amended Annual Report on Form 10-K/A to restate its consolidated financial statements for the year ended December 31, 2024 and update related disclosures. The restatement primarily reclassifies $16.4 million of non‑cash stock‑based compensation obligations for under‑construction and ramping hospitals from equity to liabilities, in line with ASC 718 and ASC 480, and incorporates several immaterial reclassifications. As a result, total liabilities at December 31, 2024 increased by $13.4 million (2.9%), total equity decreased by $13.4 million (6.6%), and net income for 2024 declined by about $0.5 million (0.5%). Diluted earnings per share decreased by $0.02 to $9.69, and basic earnings per share decreased by $0.02 to $10.23. The company reports that these non‑cash adjustments did not materially affect revenue, liquidity, debt levels, operating cash flow, adjusted EBITDA or patient volumes, but it has identified an additional material weakness in internal control over financial reporting and has engaged external advisors to help remediate its control environment.
Nutex Health Inc. filed a Form 12b-25 to notify that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company says it cannot meet the deadline without unreasonable effort and expense because it must first complete and file previously announced restatements of its 2024 Form 10-K and March 31, 2025 Form 10-Q, as well as the delayed June 30, 2025 Form 10-Q. Nutex Health received a Nasdaq notice on August 20, 2025 for not timely filing the June 30, 2025 Form 10-Q and obtained an extension to December 12, 2025, after which Nasdaq staff may issue a delisting notice if the report is still outstanding. The company also indicates that a significant change in results of operations versus the prior year is expected, with details referenced in an earlier Form 8-K, and it cautions that there is no assurance on the exact timing of the delayed filings.
Nutex Health (NUTX) filed a Form 3 for its Chief Operating Officer, Wesley Shane Bamburg. The filing states that no securities are beneficially owned by the reporting person as of the event date.
The event date is 10/15/2025, and the form was filed by one reporting person. This is a routine Section 16 initial ownership report confirming no current holdings.
Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.
The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.
Nutex Health, Inc. appointed Michael Bamburg as Chief Operating Officer and disclosed the principal terms of his employment agreement dated September 16, 2025. Bamburg, age 43, joins from HCA Houston Healthcare with a background in payor contracting and provider operations and holds a B.S. in Healthcare Administration and an MBA. The two-year agreement provides a base salary of $415,000 with automatic two-year extensions unless timely notice is given, eligibility for an annual cash bonus up to 60% of base salary, participation in long-term incentive awards valued up to 60% of base salary if granted, and a $100,000 signing bonus payable over four quarters if he remains employed at least 12 months. The agreement includes twelve months' severance and health subsidy if terminated without cause or for good reason, and standard accrual and reimbursement provisions. The filing incorporates the full agreement as Exhibit 10.1.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective September 2, 2025. Mr. Reed has been a director since April 2022 and serves on the Audit, Compensation, and Nominating and Corporate Governance Committees. In the new role he will preside over executive sessions of independent directors, facilitate communication between independent directors and the Chairman/CEO, and act as a liaison between the Board and management, consistent with the company’s governance guidelines and Nasdaq Listing Rule 5605. The appointment carries additional compensation under the company’s existing director compensation program disclosed in the proxy filed June 2, 2025.
Nutex Health Inc. reports that a putative securities class action was filed on August 22, 2025 in the U.S. District Court for the Southern District of Texas, captioned Anjana Bhagavan v. Nutex Health Inc. (Case No. 4:25-cv-03999).
The complaint names the company, its Chairman and Chief Executive Officer, its Chief Financial Officer, and its President and Director as defendants and asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The allegations track a recent short seller report, and the plaintiff seeks unspecified damages.
Nutex Health disputes the allegations and intends to vigorously defend the lawsuit. The company states it cannot predict the outcome or estimate the financial impact, but acknowledges that an adverse ruling could have a material adverse effect on its financial position or results of operations.
Nutex Health Inc. filed a current report announcing that on August 14, 2025 it issued a press release with certain anticipated financial results and related information. The company furnished this press release as Exhibit 99.1, specifying that the information in Item 2.02 and the exhibit is being provided for informational purposes and is not deemed filed under the Exchange Act, nor automatically incorporated into other securities filings unless specifically referenced.
Nutex Health Inc. filed a notice that it will be late filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The company says it needs additional time to analyze the classification of certain equity instruments and to finalize its financial statements, and that filing on time would require unreasonable effort and expense.
Nutex states it expects to file the Form 10-Q within the five-calendar-day extension period allowed under SEC rules. The company confirms that all other required periodic reports over the past 12 months have been filed. It also indicates that the upcoming Form 10-Q will reflect a significant change in results of operations compared with the same period in the prior year.